Neuroprotective effect of Vesatolimod in an experimental autoimmune encephalomyelitis mice model
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109717 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Xian Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen 518055, Guangdong, China. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Neuroprotective Agents, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Multiple sclerosis is a chronic demyelinating autoimmune disease accompanied by inflammation and loss of axons and neurons. Toll-like receptors play crucial roles in the innate immune system and inflammation. However, few studies have explored the specific effects of toll-like receptor 7 signaling pathway in multiple sclerosis. To explore underlying effects to develop a new therapeutic target, we use Vesatolimod, a safe and well-tolerated agonist of toll-like receptor 7, to assess the possible effects in Experimental autoimmune encephalomyelitis (EAE) animal model. METHODS: EAE animal model was induced by injection of MOG35-55 and monitored daily for clinical symptoms, and the treatment group was given Vesatolimod at the onset of illness. The therapeutic effects of Vesatolimod on EAE inflammation, demyelination, CD107b cells and T cells infiltration, and microglia activation was evaluated. Autophagy within the spinal cords of EAE mice was also preliminarily assessed. RESULTS: Treatment with Vesatolimod significantly alleviated clinical symptoms of EAE from day 18 post-immunization and decreased the expression levels of inflammatory cytokines, particularly Eotaxin and IL-12 (P40), in peripheral blood. It also inhibited demyelination in spinal cords. Moreover, VES treatment reduced activation of microglia, infiltration of CD3 + T cells and CD107b + cells, as well as inhibited the autophagy-related proteins expression in the spinal cords of EAE mice. CONCLUSION: Our results indicate that Vesatolimod exhibits protective effects on EAE mice and is promising for treatment of MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen 518055, Guangdong, China.
- School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518055, Guangdong, China.
- School of Psychology, Shenzhen University, Shenzhen 518060, Guangdong, China. Electronic address: mushuhua@szu.edu.cn.
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen 518055, Guangdong, China. Electronic address: jzhanghappy@163.com.
Zitieren
APA
Jiang, X., Song, Y., Fang, J., Yang, X., Mu, S., & Zhang, J. (2023). Neuroprotective effect of Vesatolimod in an experimental autoimmune encephalomyelitis mice model. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109717
Vancouver
Jiang X, Song Y, Fang J, Yang X, Mu S, Zhang J. Neuroprotective effect of Vesatolimod in an experimental autoimmune encephalomyelitis mice model. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109717
BibTeX
@article{Jiang2023,
author = {Jiang, Xian and Song, Yifan and Fang, Jie and Yang, Xiaosheng and Mu, Shuhua and Zhang, Jian},
title = {Neuroprotective effect of Vesatolimod in an experimental autoimmune encephalomyelitis mice model},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109717}
}
EUVIMED